{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:11:40Z","timestamp":1792606300233,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF19OC0058259"],"award-info":[{"award-number":["NNF19OC0058259"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","award":["R276-A16396"],"award-info":[{"award-number":["R276-A16396"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.vaccine.2025.128142","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:01:26Z","timestamp":1766494886000},"page":"128142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2+ from childhood vaccinated women: The Trial23 cohort study"],"prefix":"10.1016","volume":"73","author":[{"given":"Mette Hartmann","family":"Nonboe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeppe Bennekou","family":"Schroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Poulsgaard","family":"Frandsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsebeth","family":"Lynge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Bonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrid","family":"H\u00f8gdall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.128142_bb0005","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3390\/v10120729","article-title":"Cervical Cancer screening programs in Europe: the transition towards HPV vaccination and population-based HPV testing","volume":"10","author":"Chrysostomou","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2025.128142_bb0010","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ejca.2015.03.008","article-title":"Cervical cancer screening in Europe: quality assurance and organisation of programmes","volume":"51","author":"Elfstr\u00f6m","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.vaccine.2025.128142_bb0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical Cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.vaccine.2025.128142_bb0020","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2008.11.046","article-title":"Papillomaviruses in the causation of human cancers \u2014 a brief historical account","volume":"384","author":"Zur","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2025.128142_bb0025","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","article-title":"Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update","volume":"121","author":"Smith","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2025.128142_bb0030","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jcv.2015.11.020","article-title":"Cervical cancer screening of HPV vaccinated populations: cytology, molecular testing, both or none","volume":"76","author":"El-Zein","year":"2016","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2025.128142_bb0035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000528964","article-title":"The future role of cytology in cervical Cancer screening in the era of HPV vaccination","volume":"67","author":"Barroeta","year":"2023","journal-title":"Acta Cytol"},{"key":"10.1016\/j.vaccine.2025.128142_bb0040","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/eurpub\/ckad225","article-title":"Divergent effects of switching from cytology to HPV-based screening in the Nordic countries","volume":"34","author":"Partanen","year":"2024","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.vaccine.2025.128142_bb0045","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cmi.2019.09.006","article-title":"Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans","volume":"26","author":"Maver","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2025.128142_bb0050","article-title":"National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study","author":"Smith","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2025.128142_bb0055","first-page":"V04210327","article-title":"Phased implementation of HPV-based cervical cancer screening in Denmark","volume":"184","author":"Bonde","year":"2022","journal-title":"Ugeskr Laeger"},{"key":"10.1016\/j.vaccine.2025.128142_bb0060","unstructured":"World Health Organization. Target product profiles for human papillomavirus screening tests to detect cervical pre-cancer and cancer 2024."},{"key":"10.1016\/j.vaccine.2025.128142_bb0065","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41416-020-0850-6","article-title":"Impact of HPV vaccination on cervical screening performance: a population-based cohort study","volume":"123","author":"Lei","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2025.128142_bb0070","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical Cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.128142_bb0075","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8887672","article-title":"Cervical Cancer screening guidelines in the postvaccination era: review of the literature","volume":"2020","author":"Liverani","year":"2020","journal-title":"J Oncol"},{"key":"10.1016\/j.vaccine.2025.128142_bb0080","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/13697137.2018.1428296","article-title":"Cervical screening in HPV-vaccinated populations","volume":"21","author":"Canfell","year":"2018","journal-title":"Climacteric J Int Menopause Soc"},{"key":"10.1016\/j.vaccine.2025.128142_bb0085","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1016\/j.vaccine.2023.10.002","article-title":"The impact of over ten years of HPV vaccination in England: surveillance of type-specific HPV in young sexually active females","volume":"41","author":"Checchi","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128142_bb0090","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41416-022-01791-w","article-title":"The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot","volume":"127","author":"Rebolj","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2025.128142_bb0095","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(17)30468-1","article-title":"Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study","volume":"17","author":"Kavanagh","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128142_bb0100","doi-asserted-by":"crossref","DOI":"10.1111\/aogs.14978","article-title":"Discontinuation of cervical cancer screening for HPV-vaccinated women?","author":"Bonde","year":"2024","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.vaccine.2025.128142_bb0105","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1093\/infdis\/jiaf032","article-title":"Population-based age-period-cohort analysis of declining human papillomavirus prevalence","volume":"231","author":"Gray","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128142_bb0110","first-page":"179","article-title":"Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS\/LSIL, HSIL, or cervical cancer: what is the potential for prevention?","volume":"25","author":"Kj\u00e6r","year":"2014","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.vaccine.2025.128142_bb0115","first-page":"8","article-title":"Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche Cobas HPV real-time PCR assay","author":"Preisler","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2025.128142_bb0120","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/ijc.33157","article-title":"Prevalence of high-risk human papillomavirus after HPV-vaccination in Denmark","volume":"147","author":"Lynge","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2025.128142_bb0125","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2025.30.27.2400820","article-title":"Human papillomavirus prevalence in first, second and third cervical cell samples from women HPV-vaccinated as girls, Denmark, 2017 to 2024: data from the Trial23 cohort study","volume":"30","author":"Nonboe","year":"2025","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2025.128142_bb0130","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","article-title":"Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature","volume":"404","author":"Wei","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.128142_bb0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/LGT.0000000000000573","article-title":"Human papillomavirus same genotype persistence and risk: a systematic review","volume":"25","author":"Bonde","year":"2021","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.vaccine.2025.128142_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/LGT.0000000000000494","article-title":"Clinical utility of human papillomavirus genotyping in cervical Cancer screening: a systematic review","volume":"24","author":"Bonde","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.vaccine.2025.128142_bb0145","first-page":"8","article-title":"Danish method study on cervical screening in women offered HPV vaccination as girls (Trial23): a study protocol","author":"Thamsborg","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2025.128142_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0306044","article-title":"Screening outcome of HPV-vaccinated women: data from the Danish Trial23 cohort study","volume":"19","author":"Nonboe","year":"2024","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2025.128142_bb0155","author":"Lynge"},{"key":"10.1016\/j.vaccine.2025.128142_bb0160","unstructured":"Dansk Selskab for Gyn\u00e6kologi og Obstetrik (DSOG). Forebyggelse, udredning og behandling af dysplasi p\u00e5 Cervix. Guideline [in Danish] 2022."},{"key":"10.1016\/j.vaccine.2025.128142_bb0165","unstructured":"National Steering Group for Cervical Cancer Screening (NSLS). HPV screening of women 25\u201329 years - Flowchart n.d. https:\/\/www.regionshospitalet-randers.dk\/siteassets\/afdelinger\/afdeling-for-folkeundersogelser\/national-styregruppe-for-livmoderhalskraftscreening\/dokumentsamling\/flowchart-30-59-ar-hpv-3-stk.-nsls-godkendt-den-17.-juni-2020.pdf."},{"key":"10.1016\/j.vaccine.2025.128142_bb0170","doi-asserted-by":"crossref","unstructured":"Ritu Nayar, David C. Wilbur, editors. The Bethesda System for Reporting Cervical Cytology. 3rd ed. 2015. Doi: https:\/\/doi.org\/10.1007\/978-3-319-11074-5.","DOI":"10.1007\/978-3-319-11074-5"},{"key":"10.1016\/j.vaccine.2025.128142_bb0175","unstructured":"Seegene Inc n.d. https:\/\/www.seegene.com\/assays\/allplex_hpv28_detection (accessed February 13, 2025)."},{"key":"10.1016\/j.vaccine.2025.128142_bb0180","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"The FUTURE ll Study Group*","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.128142_bb0185","unstructured":"National Institution of public health (NIPH). School survey 2010 [in Danish]. 2011."},{"key":"10.1016\/j.vaccine.2025.128142_bb0190","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/aogs.13935","article-title":"High-grade cervical lesions after vaccination against human papillomavirus: a Danish cohort study","volume":"99","author":"Thamsborg","year":"2020","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.vaccine.2025.128142_bb0195","doi-asserted-by":"crossref","unstructured":"Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early Impact of Human Papillomavirus Vaccination on Cervical Neoplasia--Nationwide Follow-up of Young Danish Women. JNCI J Natl Cancer Inst 2014;106:djt460\u2013djt460. Doi: https:\/\/doi.org\/10.1093\/jnci\/djt460.","DOI":"10.1093\/jnci\/djt460"},{"key":"10.1016\/j.vaccine.2025.128142_bb0200","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1002\/ijc.32848","article-title":"Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: population-based nested case\u2013control study","volume":"146","author":"Kann","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2025.128142_bb0205","doi-asserted-by":"crossref","first-page":"6304","DOI":"10.1016\/j.vaccine.2020.07.037","article-title":"HPV16\/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination","volume":"38","author":"Cornall","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128142_bb0210","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/vaccines10020188","article-title":"Changes in HPV16\/18 prevalence among unvaccinated women with cervical intraepithelial neoplasia in Japan: assessment of herd effects following the HPV vaccination program","volume":"10","author":"Onuki","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.128142_bb0215","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41416-023-02386-9","article-title":"The changing nature of HPV associated with high grade cervical lesions in vaccinated populations, a retrospective study of over 1700 cases in Scotland","volume":"129","author":"Cuschieri","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2025.128142_bb0220","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bpobgyn.2017.08.015","article-title":"The natural history of human papillomavirus infection","volume":"47","author":"De Sanjos\u00e9","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.vaccine.2025.128142_bb0225","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.virol.2005.04.002","article-title":"The carcinogenicity of human papillomavirus types reflects viral evolution","volume":"337","author":"Schiffman","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2025.128142_bb0230","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3390\/v16081245","article-title":"Update on effects of the prophylactic HPV vaccines on HPV type prevalence and cervical pathology","volume":"16","author":"Hampson","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2025.128142_bb0235","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(22)00291-1","article-title":"Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV vaccine trial","volume":"23","author":"Shing","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2025.128142_bb0240","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ijc.29374","article-title":"Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology","volume":"137","author":"Thomsen","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2025.128142_bb0245","unstructured":"IARC. List of Classifications \u2013 IARC Monographs on the Identification of Carcinogenic Hazards to Humans 2024. https:\/\/monographs.iarc.who.int\/list-of-classifications (accessed November 29, 2022)."},{"key":"10.1016\/j.vaccine.2025.128142_bb0250","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/infdis\/jit577","article-title":"No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study","volume":"209","author":"Wentzensen","year":"2014","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25014409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25014409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:30:47Z","timestamp":1773923447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25014409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":50,"alternative-id":["S0264410X25014409"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128142","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2+ from childhood vaccinated women: The Trial23 cohort study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128142"}}